NeoTract Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference

PLEASANTON, Calif.–(BUSINESS WIRE)–NeoTract, Inc., a medical device company that markets the UroLift®
System for treating enlarged prostate, today announced that it will
present at the 35th Annual J.P. Morgan Healthcare Conference. Dave
Amerson, President and CEO of NeoTract Inc., is scheduled to present on
Monday, January 9th at 1:30pm PT at the Westin St. Francis in
San Francisco, CA.

About the UroLift System

The FDA-cleared UroLift System is a novel, minimally invasive technology
for treating lower urinary tract symptoms due to benign prostatic
hyperplasia (BPH) also known as enlarged prostate. The UroLift permanent
implants, delivered during a minimally invasive transurethral outpatient
procedure, relieve prostate obstruction and open the urethra directly
without cutting, heating, or removing prostate tissue. Clinical data
from a pivotal 206-patient randomized controlled study showed that
patients with enlarged prostate receiving UroLift implants reported
rapid and durable symptomatic and urinary flow rate improvement without
compromising sexual function. Patients also experienced a significant
improvement in quality of life. Most common adverse events reported
include hematuria, dysuria, micturition urgency, pelvic pain, and urge
incontinence. Most symptoms were mild to moderate in severity and
resolved within two to four weeks after the procedure. The UroLift
System is available in the U.S., Europe, Australia and Canada. Learn
more at

About NeoTract

NeoTract, Inc. is dedicated to developing innovative, minimally invasive
and clinically effective devices that address unmet needs in the field
of urology. The company’s initial focus is on improving the standard of
care for patients with BPH using the UroLift System, a minimally
invasive permanent implant system that treats symptoms while preserving
normal sexual function. Learn more at


Investor Contact:
The Ruth Group
Nick Laudico,

Nicole Osmer, 650-454-0505